1. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade
- Author
-
Charlotte E. Ariyan, Christopher M. Tipton, Robert A. Lefkowitz, Jorge Blando, Mary Sue Brady, Jian Hu, Padmanee Sharma, Harlan Robins, Danielle M. Bello, Jedd D. Wolchok, Achim A. Jungbluth, Kathleen S. Panageas, James P. Allison, Charles Fisher, Melissa Pulitzer, Jianda Yuan, R.H. Siegelbaum, Jamie Rand, Taha Merghoub, Marissa Vignali, Ryan O. Emerson, and Alexander Y. Rudensky
- Subjects
0301 basic medicine ,Melphalan ,Male ,Cancer Research ,medicine.medical_treatment ,Immunology ,Melanoma, Experimental ,Ipilimumab ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,CTLA-4 Antigen ,Melanoma ,Tumor microenvironment ,business.industry ,Immunotherapy ,medicine.disease ,Combined Modality Therapy ,Nitrogen mustard ,Blockade ,Mice, Inbred C57BL ,030104 developmental biology ,chemistry ,CTLA-4 ,030220 oncology & carcinogenesis ,Cancer research ,Dactinomycin ,business ,medicine.drug - Abstract
Clinical responses to immunotherapy have been associated with augmentation of preexisting immune responses, manifested by heightened inflammation in the tumor microenvironment. However, many tumors have a noninflamed microenvironment, and response rates to immunotherapy in melanoma have been
- Published
- 2018